FTC Launches ‘Colonoscopy’ Into PBM Practices, Including Focus On Consumer Costs, Access
Study will examine how the six largest pharmacy benefit managers in the US handle 10 disease categories. Federal Trade Commissioners unanimously support inquiry after its scope was broadened from an earlier version that drew objections from Republicans.
You may also be interested in...
FTC Expands PBM Probe To Group Purchasing Organizations
Commission issues compulsory orders for information to two organizations that negotiate drug rebates on behalf of CVS Caremark, Express Scripts and other PBMs. It issued similar orders to the six largest PBMs last year.
US MedPAC Opens Another Front For New PBM Policies
Medicare Payment Advisory Commission appears ready to open yet another front in investigations and policy recommendations regarding PBM practices as it continues to dig into newly available data on rebates in the Part D program.
PBM Impact On Off-Patent Industry Condemned At Senate Hearing
Witnesses at a US Senate Finance Committee Hearing have condemned the impact the “perverse” practices of pharmacy benefit managers have on off-patent drugs, often placing them on non-preferred tiers so that patients must use more expensive, branded medication.